MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00266344|
Recruitment Status : Completed
First Posted : December 16, 2005
Last Update Posted : January 14, 2015
|Condition or disease||Intervention/treatment||Phase|
|Primary Insomnia||Drug: MK0928, gaboxadol / Duration of Treatment 3 Weeks Drug: Placebo / Duration of Treatment 3 Weeks||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||520 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||MK0928 Phase IIb Dose-range Finding Study -Primary Insomnia|
|Study Start Date :||November 2005|
|Study Completion Date :||October 2006|
- Patient-reported total sleep time.
- Patient-reported time to sleep onset, number of awakenings, wake time after sleep onset and premature awakening.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00266344
|Study Director:||Medical Monitor||Merck Sharp & Dohme Corp.|